{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:32:15Z","timestamp":1782732735657,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007033","name":"Eisai Korea Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ygyno.2021.06.032","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T03:20:18Z","timestamp":1626232818000},"page":"619-625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer"],"prefix":"10.1016","volume":"162","author":[{"given":"Floor J.","family":"Backes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Dzwigalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Poi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Salani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Bixel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.06.032_bb0005","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0010","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.06.032_bb0015","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.5520","article-title":"A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes","volume":"31","author":"Vergote","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2019.12.039","article-title":"Second-line lenvatinib in patients with recurrent endometrial cancer","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.06.032_bb0025","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0030","series-title":"Lenvatinib Prescribing Information","year":"2020"},{"key":"10.1016\/j.ygyno.2021.06.032_bb0035","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus Pembrolizumab in patients with advanced endometrial Cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s10147-007-0731-5","article-title":"A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer","volume":"13","author":"Homesley","year":"2008","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2006.01.030","article-title":"Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer","volume":"102","author":"Cohn","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0050","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ygyno.2011.01.009","article-title":"Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer","volume":"121","author":"O\u2019Malley","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0060","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, Pegylated liposomal doxorubicin, or Topotecan in platinum-resistant recurrent ovarian Cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0065","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0070","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0075","first-page":"16","article-title":"Paclitaxel pharmacokinetics and pharmacodynamics","volume":"22","author":"Kearns","year":"1995","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2165\/00003088-199427040-00002","article-title":"Clinical pharmacokinetics of paclitaxel","volume":"27","author":"Sonnichsen","year":"1994","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrclinonc.2010.216","article-title":"Emerging therapeutic targets in endometrial cancer","volume":"8","author":"Dedes","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0090","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0095","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/oxfordjournals.annonc.a058838","article-title":"Phase I\/II study of intraperitoneal mitoxantrone in refractory ovarian cancer","volume":"5","author":"Oza","year":"1994","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2017.4218","article-title":"Paclitaxel with and without Pazopanib for persistent or recurrent ovarian Cancer: a randomized clinical trial","volume":"4","author":"Richardson","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0105","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0115","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40261-014-0217-y","article-title":"Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults","volume":"34","author":"Shumaker","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0120","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5414\/CP201937","article-title":"Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers","volume":"52","author":"Shumaker","year":"2014","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0125","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/1078-0432.CCR-15-1354","article-title":"Safety and pharmacokinetics of Lenvatinib in patients with advanced hepatocellular carcinoma","volume":"22","author":"Ikeda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00280-016-3098-3","article-title":"Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors","volume":"78","author":"Chow","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2021.06.032_bb0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40262-017-0563-z","article-title":"Clinical pharmacokinetics of paclitaxel monotherapy: an updated literature review","volume":"57","author":"Stage","year":"2018","journal-title":"Clin. Pharmacokinet."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582100528X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582100528X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:56:45Z","timestamp":1758772605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582100528X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S009082582100528X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.06.032","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}